Uncategorized
Travatan approved in EU for pediatric glaucoma patients
The European Commission has granted Travatan eye drop solution an additional indication to treat pediatric patients with ocular hypertension or pediatric glaucoma, Alcon announced in a Novartis press release.The new indication of Travatan (40 µg/mL travoprost) is to decrease IOP in patients between the ages of 2 months and less than 18 years. It was previously approved for adult patients with ocular hypertension or open-angle glaucoma.